Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 548

1.

Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis.

Borz B, Durand E, Godin M, Tron C, Canville A, Litzler PY, Bessou JP, Cribier A, Eltchaninoff H.

Heart. 2013 Jun;99(12):860-5. doi: 10.1136/heartjnl-2012-303095. Epub 2012 Dec 12.

PMID:
23236027
2.

Incidence, predictors and prognostic value of serious hemorrhagic complications following transcatheter aortic valve implantation.

Amabile N, Azmoun A, Ghostine S, Ramadan R, Haddouche Y, Raoux F, To NT, Troussier X, Nottin R, Caussin C.

Int J Cardiol. 2013 Sep 20;168(1):151-6. doi: 10.1016/j.ijcard.2012.09.025. Epub 2012 Oct 16.

PMID:
23079085
3.

Procedural results and 30-day clinical events analysis following Edwards transcatheter aortic valve implantation in 48 consecutive patients: initial experience.

Zhao QM, Lognone T, Ivascau C, Sabatier R, Roule V, Dahdouh Z, Massetti M, Grollier G.

Chin Med J (Engl). 2012 Aug;125(16):2807-10.

PMID:
22932071
4.

Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve).

Généreux P, Cohen DJ, Williams MR, Mack M, Kodali SK, Svensson LG, Kirtane AJ, Xu K, McAndrew TC, Makkar R, Smith CR, Leon MB.

J Am Coll Cardiol. 2014 Mar 25;63(11):1100-9. doi: 10.1016/j.jacc.2013.10.058. Epub 2013 Nov 27.

5.

Transfemoral aortic valve replacement with the Edwards SAPIEN and Edwards SAPIEN XT prosthesis using exclusively local anesthesia and fluoroscopic guidance: feasibility and 30-day outcomes.

Durand E, Borz B, Godin M, Tron C, Litzler PY, Bessou JP, Bejar K, Fraccaro C, Sanchez-Giron C, Dacher JN, Bauer F, Cribier A, Eltchaninoff H.

JACC Cardiovasc Interv. 2012 May;5(5):461-7. doi: 10.1016/j.jcin.2012.01.018. Epub 2012 May 9.

6.

Prospective analysis of 30-day safety and performance of transfemoral transcatheter aortic valve implantation with Edwards SAPIEN XT versus SAPIEN prostheses.

Eltchaninoff H, Durand E, Borz B, Godin M, Tron C, Litzler PY, Bessou JP, Bejar K, Fraccaro C, Sanchez-Giron C, Dacher JN, Bauer F, Cribier A.

Arch Cardiovasc Dis. 2012 Mar;105(3):132-40. doi: 10.1016/j.acvd.2012.02.002. Epub 2012 Mar 16.

7.

Transcatheter aortic valve implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving system devices: a multicenter collaborative study: the PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration).

Chieffo A, Buchanan GL, Van Mieghem NM, Tchetche D, Dumonteil N, Latib A, van der Boon RM, Vahdat O, Marcheix B, Farah B, Serruys PW, Fajadet J, Carrié D, de Jaegere PP, Colombo A.

J Am Coll Cardiol. 2013 Feb 26;61(8):830-6. doi: 10.1016/j.jacc.2012.11.050. Epub 2013 Jan 16.

8.

A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events in patients undergoing transfemoral versus transapical transcatheter aortic valve implantation using edwards valve for severe aortic stenosis.

Panchal HB, Ladia V, Amin P, Patel P, Veeranki SP, Albalbissi K, Paul T.

Am J Cardiol. 2014 Dec 15;114(12):1882-90. doi: 10.1016/j.amjcard.2014.09.029. Epub 2014 Sep 28. Review.

PMID:
25438917
9.

Effect of transcatheter (via femoral artery) aortic valve implantation on the platelet count and its consequences.

Gallet R, Seemann A, Yamamoto M, Hayat D, Mouillet G, Monin JL, Gueret P, Couetil JP, Dubois-Randé JL, Teiger E, Lim P.

Am J Cardiol. 2013 Jun 1;111(11):1619-24. doi: 10.1016/j.amjcard.2013.01.332. Epub 2013 Mar 20.

PMID:
23523059
10.

Incidence and predictors of left bundle branch block after transcatheter aortic valve implantation.

Aktug Ö, Dohmen G, Brehmer K, Koos R, Altiok E, Deserno V, Herpertz R, Autschbach R, Marx N, Hoffmann R.

Int J Cardiol. 2012 Sep 20;160(1):26-30. doi: 10.1016/j.ijcard.2011.03.004. Epub 2011 Mar 31.

PMID:
21458085
11.

European experience with the second-generation Edwards SAPIEN XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT Registry.

Schymik G, Lefèvre T, Bartorelli AL, Rubino P, Treede H, Walther T, Baumgartner H, Windecker S, Wendler O, Urban P, Mandinov L, Thomas M, Vahanian A.

JACC Cardiovasc Interv. 2015 Apr 27;8(5):657-69. doi: 10.1016/j.jcin.2014.10.026.

12.

Safety and effectiveness of a selective strategy for coronary artery revascularization before transcatheter aortic valve implantation.

Gasparetto V, Fraccaro C, Tarantini G, Buja P, D'Onofrio A, Yzeiraj E, Pittarello D, Isabella G, Gerosa G, Iliceto S, Napodano M.

Catheter Cardiovasc Interv. 2013 Feb;81(2):376-83. doi: 10.1002/ccd.24434. Epub 2012 May 2.

PMID:
22461314
13.

The STS score is the strongest predictor of long-term survival following transcatheter aortic valve implantation, whereas access route (transapical versus transfemoral) has no predictive value beyond the periprocedural phase.

Hemmann K, Sirotina M, De Rosa S, Ehrlich JR, Fox H, Weber J, Moritz A, Zeiher AM, Hofmann I, Schächinger V, Doss M, Sievert H, Fichtlscherer S, Lehmann R.

Interact Cardiovasc Thorac Surg. 2013 Aug;17(2):359-64. doi: 10.1093/icvts/ivt132. Epub 2013 May 3.

14.

Transcatheter Edwards Sapien XT valve in valve implantation in degenerated aortic bioprostheses via transfemoral access.

Greif M, Lange P, Mair H, Becker C, Schmitz C, Steinbeck G, Kupatt C.

Clin Res Cardiol. 2012 Dec;101(12):993-1001. doi: 10.1007/s00392-012-0488-3. Epub 2012 Jun 23.

PMID:
22729757
15.

Midterm outcomes after transcatheter aortic valve implantation.

Lotfi S, Dohmen G, Götzenich A, Haushofer M, Spillner JW, Autschbach R, Hoffmann R.

Innovations (Phila). 2014 Sep-Oct;9(5):343-7; discussion 348. doi: 10.1097/IMI.0000000000000097.

PMID:
25238419
16.

Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis.

Pilgrim T, Stortecky S, Luterbacher F, Windecker S, Wenaweser P.

J Thromb Thrombolysis. 2013 May;35(4):456-62. doi: 10.1007/s11239-012-0842-3.

PMID:
23143652
17.

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study.

Lefèvre T, Kappetein AP, Wolner E, Nataf P, Thomas M, Schächinger V, De Bruyne B, Eltchaninoff H, Thielmann M, Himbert D, Romano M, Serruys P, Wimmer-Greinecker G; PARTNER EU Investigator Group.

Eur Heart J. 2011 Jan;32(2):148-57. doi: 10.1093/eurheartj/ehq427. Epub 2010 Nov 12.

18.

Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions.

Seiffert M, Schnabel R, Conradi L, Diemert P, Schirmer J, Koschyk D, Linder M, Kersten JF, Grosser A, Wilde S, Blankenberg S, Reichenspurner H, Baldus S, Treede H.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):640-52. doi: 10.1002/ccd.24751. Epub 2013 Mar 18.

PMID:
23172652
19.

Early clinical outcome of aortic transcatheter valve-in-valve implantation in the Nordic countries.

Ihlberg L, Nissen H, Nielsen NE, Rück A, Busund R, Klaarborg KE, Soendergaard L, Harnek J, Miettinen H, Eskola M, Wahba A, Laine M.

J Thorac Cardiovasc Surg. 2013 Nov;146(5):1047-54; discussion 1054. doi: 10.1016/j.jtcvs.2013.06.045. Epub 2013 Aug 30.

20.

Occurrence and prognostic impact of systemic inflammatory response syndrome in transfemoral and transapical aortic valve implantation with balloon- and self-expandable valves.

Schwietz T, Behjati S, Gafoor S, Seeger F, Doss M, Sievert H, Zeiher AM, Fichtlscherer S, Lehmann R.

EuroIntervention. 2015 Apr;10(12):1468-73. doi: 10.4244/EIJY14M06_05.

Supplemental Content

Support Center